Announcement PDF Emyria ASX Announcement | 22 June 2026 1 ASX RELEASE. 22 June 2026 Emyria Formalises NSW Workforce Ahead of First Sydney Clinic Opening Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”), a leader in delivering evidence- based mental-health treatments, is pleased to announce that it has completed training for its first cohort of Sydney therapists ahead of the planned Q3 CY2026 opening of the Company’s first NSW-based Empax clinic, located at Matilda Nepean1 . Following the NSW clinical workforce recruitment campaign announced in April2 , a total of 25 contracted therapists and 6 psychiatrists were trained over the weekend by Empax. These clinicians join a growing clinical workforce of over 100+ existing contracted and trained psychiatrists and therapists across Australia. The training is a catalysing step as the Company progresses towards the establishment of a fourth state-based clinical operation, joining existing centres across Western Australia, Queensland and Victoria. The training also builds on additional core operational elements in progress for the opening of the Sydney clinic, with medication secured, and fit-out requirements within Matilda Nepean being finalised. Training and planned clinic opening meets growing demand for new therapies The clinical training and continued progress towards the opening of a Sydney clinic comes at a time of growing demand for evidence-based mental health therapies in NSW. The state represents Australia’s largest addressable patient population, with over 1.8 million people in NSW having a long-term mental or behavioural condition3 , and psychological injuries having increased 64% since 2019-204 . Emyria Executive Director Greg Hutchinson commented: “The completion of clinician training in NSW is a positive step in Emyria’s national expansion efforts. We are well-positioned to be able to deliver new therapies for the many people suffering complex mental health conditions who need access to treatment. With the Sydney clinic opening on track for Q3 CY2026, we are also pleased to confirm that we are delivering in line with our stated corporate milestones.” • First cohort of NSW Contracted Clinicians trained – 25 therapists and 6 psychiatrists completed the Empax training program in Sydney over the weekend. • Growing clinical workforce across Australia – NSW trained clinicians join an established network of over 100+ trained Clinicians across Western Australia, Victoria, and Queensland. • Sydney clinic opening on track– Recruitment and training is a foundational step for a new Empax clinic with the first Sydney-based Empax clinic located at Matilda Nepean set to open in Q3 CY2026. • Australia’s largest addressable population – NSW represents Australia’s largest target patient market, with demand for innovative therapies growing. ASX RELEASE. Emyria ASX Announcement | 22 June 2026 2 References: 1 See ASX release 2 April 2026 2 See ASX release 29 April 2026 3 https://www.nswmentalhealthcommission.com.au/measuring-change-indicator/prevalence-mental-health-issues 4 https://www.sira.nsw.gov.au/__data/assets/pdf_file/0004/1336999/SIRA_Annual-Report-2023-24.pdf This release has been approved by the Board of Emyria. For further information, investment opportunities, or more about Emyria’s approach to mental health treatment, please contact: Greg Hutchinson Executive Chair 1300 153 355 | investors@emyria.com ASX RELEASE. Emyria ASX Announcement | 22 June 2026 3 CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations, plans and prospects for the Company, the Company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. Risks associated with the use of MDMA, MDMA-inspired compounds and psilocybin All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess the suitability of a new medication against a patient’s individual circumstances and medical history before proceeding. Adverse effects of MDMA include high blood pressure, increased pulse rate, faintness, and panic attacks, and in some rare cases it can cause loss of consciousness or trigger seizures. Other side effects include involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating and muscle/joint stiffness. Adverse effects of psilocybin can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. The effects of MDMA and psilocybin are unlikely at low doses in the treatment regimens used in psychedelic-assisted psychotherapy while appropriately managed in a controlled environment with direct medical supervision. The risk profile of the MDMA inspired compounds is currently unknown. The availability of these products is subject to the safety and efficacy of the products being tested through clinical trials. Emyria makes no representations or warranties as to the safety or efficacy of the products or the products’ ability (or the ability of its key compounds) to be used in the treatment of indications such as PTSD. There are currently no approved products containing MDMA, psilocybin or MDMA inspired compounds that the TGA has evaluated for quality, safety and efficacy. Emyria Limited develops and delivers new treatments for mental health and select neurological conditions through an integrated model of direct clinical services and treatment development: Emyria Healthcare: Evidence-based treatment for patients not finding relief from conventional care while also helping evaluate emerging new therapies like assisted therapy for PTSD and assisted therapy for treatment-resistant depression. Emyria Data: Robust and ethically sourced Real-World Data gathered with patients to improve Emyria’s unique therapy and drug development programs. Emyria’s Pipeline: New psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases. EMYRIA’S INTERACTIVE INVESTOR HUB Investorhub.emyria.com Interact with Emyria’s announcements and updates by asking questions and comments, which our team can respond to where possible. generates informs